AMGN vs GILD — Key Metrics
| Metric | AMGN (AMGEN INC) | GILD (GILEAD SCIENCES INC) |
|---|---|---|
| Price | 421.51 | 149.05 |
| Market Cap | 227.88 Billion | 184.82 Billion |
| P/E (TTM) | 25.99 | -57.33 |
| P/B (Quarterly) | 18.864 | 13.717 |
| P/S (TTM) | 5.98 | 6.07 |
| Net Profit Margin (TTM) | 23.0 | -10.6 |
| Gross Margin (TTM) | 69.5 | 79.6 |
| ROE (TTM) | 89.3 | -16.3 |
| Revenue Growth YoY (TTM) | None | None |
Upfront Investment - S&P 500 Stock Comparison & AI Analysis
AI-powered analysis and comparison tools for S&P 500 stocks, helping investors make data-driven decisions with delayed market data and portfolio modeling.
Performance Comparison
AI Model Recommendation
AMGN · AMGEN INC
Outperform
GILD · GILEAD SCIENCES INC
Outperform
Recommendation Summary
Both stocks are projected to outperform the market over the next year. If you have to make a choice, Upfront Recommendation: AMGN.
Financial Metrics
Prices delayed ~15 min
| AMGN | Metrics | GILD |
|---|---|---|
| $421.51 | Price | $149.05 |
| — | Market Capitalization | — |
| 5.98 | Price to Sales | 6.07 |
| 22.4 | Price to FCF Ratio | 14.28 |
| 8.61 | Price to Gross Profit | 7.62 |
| 29.87 | Price to R&D | 30.47 |
| 6.52 | Price to Current Assets | 13.25 |